Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1
Active, not recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Kathryn Gold
- Target Recruit Count
- 24
- Registration Number
- NCT03498378
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
© Copyright 2025. All Rights Reserved by MedPath